These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30920034)

  • 1. Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.
    Chen CH
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1106-1107. PubMed ID: 30920034
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients.
    Huang R; Yao R; Wu W; Wang J; Wu C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1105-1106. PubMed ID: 30920033
    [No Abstract]   [Full Text] [Related]  

  • 3. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
    Su TH; Yang HC; Tseng TC; Liou JM; Liu CH; Chen CL; Chen PJ; Chen DS; Liu CJ; Kao JH
    J Infect Dis; 2018 Mar; 217(8):1193-1201. PubMed ID: 29300980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
    Pol S; Lusivika Nzinga C; Carrat F
    Aliment Pharmacol Ther; 2021 May; 53(9):1050. PubMed ID: 33831235
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Doğan ÜB; Kara B; Gümürdülü Y; Soylu A; Akin MS
    Turk J Gastroenterol; 2012 Jun; 23(3):247-52. PubMed ID: 22798114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis.
    Dogan Z; Filik L; Ergül B; Sarikaya M
    Saudi J Gastroenterol; 2015; 21(6):396-9. PubMed ID: 26655136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-To-Head Comparison of Two Years Efficacy of Entecavir and Tenofovir in Patients with Treatment-Naïve Chronic Hepatitis B--The Real Life Data.
    Hepatogastroenterology; 2015 Jun; 62(140):982-6. PubMed ID: 26902041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
    Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
    Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients.
    Höner Zu Siederdissen C; Hui AJ; Sukeepaisarnjaroen W; Tangkijvanich P; Su WW; Nieto GEG; Gineste P; Nitcheu J; Crabé S; Stepien S; Manns MP; Trépo C; Wedemeyer H; Cornberg M
    J Infect Dis; 2018 Sep; 218(9):1480-1484. PubMed ID: 29893893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
    Kuo MT; Hu TH; Hung CH; Wang JH; Lu SN; Tsai KL; Chen CH
    Aliment Pharmacol Ther; 2019 Jan; 49(2):218-228. PubMed ID: 30484881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
    Gao L; Trinh HN; Li J; Nguyen MH
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1339-40. PubMed ID: 24803254
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Eur J Intern Med; 2022 Sep; 103():122-125. PubMed ID: 35835625
    [No Abstract]   [Full Text] [Related]  

  • 14. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.
    Zuo SR; Zuo XC; Wang CJ; Ma YT; Zhang HY; Li ZJ; Song LY; Deng ZZ; Liu SK
    J Clin Pharmacol; 2015 Mar; 55(3):288-97. PubMed ID: 25293471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
    J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis.
    Chen J; Zhao SS; Liu XX; Huang ZB; Huang Y
    Clin Ther; 2017 Sep; 39(9):1870-1880. PubMed ID: 28797777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B.
    Yegin EG; Ozdogan OC
    Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):602-11. PubMed ID: 25475862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.
    Yip TC; Wong GL
    Aliment Pharmacol Ther; 2020 Jan; 51(2):315-316. PubMed ID: 31880016
    [No Abstract]   [Full Text] [Related]  

  • 19. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
    Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
    Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.